2024. COST-EFFECTIVENESS OF BEVACIZUMAB AND RANIBIZUMAB AS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR PATIENTS WITH EYE DISORDERS: A SYSTEMATIC REVIEW. Kartika Jurnal Ilmiah Farmasi. 9, 1 (Apr. 2024), 37–53. DOI:https://doi.org/10.26874/kjif.v9i1.658.